Anti-Human CD25 Azide Free
Product Specifications
- Catalogue N°
- 852.000.000 - 200µg / 200µl
852.000.005 - 500µg / 500µl - Target species
- Human
- Specificity
- Recognises the Interleukin 2 Receptor a chain (IL-2 Ra), a 55 kDa protein
- Clone
- B-B10
- Application
- Flow Cytometry
- Immunohistochemistry
- Functional assay
- Hybridoma
- Myeloma X63/AG.8653 x Balb/c spleen cells
- Immunisation
- PHA activated T cells
- Quantity
- 200µg or 500µg (Discovery Size also available please enquire)
- Isotype
- Mouse IgG1 Kappa light chain
- Format
- Phosphate-buffered saline. Sterile-filtered through 0.22 μm. Carrier and preservative free
- Workshop
- IV-V
- Storage
- Stable at +2-8°C for 12 months. For longer storage freeze aliquots.
- Biological Activity
- Inhibits mixed lymphocyte culture
- Synonym
- IL-2R α-Chain
References
- Charlot-Rabiega, P. et al., J. Biol. Chem., 2011; 286: 27350 - 27362 - Pubmed link
- Engert, A. et al., Int J Cancer,1991; 49(3): 450-6. - Pubmed link
- Groux, H. et al., J Immunol.,1998; 160(7): 3188-93. - Pubmed link
- Herbelin, C. et al., Bone Marrow Transplant,1994; 13(5): 563-9. - Pubmed link
- Herve, P. et al., Blood,1990; 75(4): 1017-23. - Pubmed link
- Herve, P. et al., Lancet,1988; 2(8619): 1072-3. - Pubmed link
- Heyll, A. et al., Dtsch Med Wochenschr.,1991; 116(22): 852-6. - Pubmed link
- Kap, Y. S. et al., Journal of Histochemistry & Cytochemistry,2009;57(12):1159-1167. - Pubmed link
- Mousson, C. et al., Transplant Proc.,1995; 27(2): 1727-8. - Pubmed link
- Nakatani, T. et al., Protein Eng.1994; 7(3): 435-43. - Pubmed link
- Nevill, T. J. et al., Blood,1998; 92(6): 1910-7. - Pubmed link
- Oppmann, B. et al., Immunity,2000; 13(5): 715-25. - Pubmed link
- Ozsahin, H. et al., Blood,1998; 92(8): 2719-24. - Pubmed link
- Racadot, E. et al., Bone Marrow Transplant,1995; 15(5): 669-77. - Pubmed link
- Racadot, E. et al., Transplant Proc.,1995; 27(2): 1672-3. - Pubmed link
- Regeer, R. R. and D. Markovich, Am J Physiol Cell Physiol.,2004; 287(2): C365-72. - Pubmed link
- Tazzari, P. L. et al., Transplantation,1992; 54(2): 351-6. - Pubmed link
- Tiberghien, P. et al., Transplantation,1991; 52(3): 475-80. - Pubmed link
- Wijdenes, J. et al., Dev Biol Stand.,1990; 71: 103-11. - Pubmed link
- Zambello, R. et al., Blood,1997; 89(1): 201-11. - Pubmed link
Related products
- 952.002.010 - Anti-Human CD25 PE Conjugated
- 852.004.010 - Anti-Human CD25 Biotinylated
- 852.010.000 - Anti-Human CD25 Azide Free
- 952.011.010 - Anti-Human CD25 FITC Conjugated
- 852.013.020 - Anti-Human CD25 Unconjugated
- 852.020.000 - Anti-Human CD25 Azide Free
- 879.500.001 - Anti-Human CD25 Capture Antibody
- 879.500.002 - Anti-Human CD25 Detection Antibody
- 950.500.048 - Human CD25 ELISA kit
- 851.650.001 - Human CD25 ELISA Set
BACKGROUND
IL-2, one of the most important factors in the human immune system, is a potent T-cell growth factor whose major function is the activation of many cells of the immune system including T-cells, B-cells, macrophages and NK cells. These potent actions are mediated by IL-2 binding and signalling through its associated cell surface receptor IL-2R. This receptor is not expressed on normal or unstimulated lymphocytes but is quickly transcribed and expressed on T-cells following activation.
This IL-2R is a heterotrimeric protein consisting of three distinct glycopeptide subunits termed IL-2Ra (CD25) specific to IL-2R, IL-2Rb and IL-2Rg. The a and b chains are involved in binding IL-2 while the signal transduction following IL-2 binding is mediated by the g-chain along with the b chain. The IL-2Ra chain or CD25 is a type 1 transmembrane glycoprotein of 251 amino acids and 55kDa. CD25 can also be found as a soluble form in serum and tissue following enzymatic cleavage from expressing cells and can be identified as a 45KDa protein once shed from the membrane. As the expression and subsequent release of CD25 takes place following cell stimulation the presence of soluble CD25 (sCD25) in circulation is an excellent marker of T-cell activation.
A number of disease states linked to over expression of CD25 have previously been described including, autoimmune diseases, transplant rejection, chronic infection, B-cell neoplasm and various types of leukaemia and other forms of cancer. Because of this definite link between CD25 over expression and disease state many therapies for these conditions have evolved to inhibit this over expression of IL-2Ra.
More recently CD25 has become the major marker for distinguishing the CD4+CD25+ subset of T regulatory cells.
Version 11 - 05.21
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.